Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis

Background: Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy. In the phase III XTEND-1 (NCT04161495) study, once-weekly efanesoctocog alfa prophylaxis (50 IU/kg) was well-tolerated and achieved high-sustained factor levels in the normal to near-normal ran...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Sophie Susen, Roshni Kulkarni, Keiji Nogami, Flora Peyvandi, Barbara Konkle, Elena Santagostino, Umer Khan, Annemieke Willemze, Linda Bystrická, Jennifer Dumont, Pratima Chowdary
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	SAGE Publishing 2026-01-01
Saila:	Therapeutic Advances in Hematology
Sarrera elektronikoa:	https://doi.org/10.1177/20406207251398986
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!